Back to top
more

Fresenius Medical Care AG & Co. (FMS)

(Delayed Data from NYSE)

$18.97 USD

18.97
278,277

+0.37 (1.99%)

Updated Apr 17, 2024 04:00 PM ET

After-Market: $18.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day

Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue?

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?

Paragon 28, Inc. (FNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Fresenius Medical (FMS) to Unveil Training on Augmented Reality

Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.

Fresenius Medical (FMS) Divests Assets to Optimize Portfolio

Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.

Davita (DVA) Shares Gain This Week: Will the Rally Continue?

DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.

Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up

Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company???s transformational plans continue to benefit its operating income.

Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System

Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fresenius Medical (FMS) Ups '23 Outlook After Legal Settlement

Fresenius Medical (FMS) wins legal dispute against the U.S. government. Both revenues and operating income will benefit from the settlement agreement.

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Indrajit Bandyopadhyay headshot

Medical Product Stocks' Q3 Earnings Due on Nov 1: SYK & More

Third-quarter results of Medical Product companies are likely to reflect a year-over-year decline. Let's see how SYK, COR, BAX, FMS and XRAY fare this time around.

Santanu Roy  headshot

NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day

NeoGenomics and SolarEdge Technologies are part of the Zacks Bull and Bear of the Day article.

Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen

Fresenius Medical Care, Vericel and ImmunoGen are part of the Zacks Investment Ideas article.

Shaun Pruitt headshot

Top Medical Stocks to Buy Amid Recent Market Volatility

Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.

DaVita's (DVA) Latest Partnership to Improve Kidney Care

DaVita's (DVA) new tie-up is likely to enable it to harness Google Cloud's AI and analytics tools to improve care plans and streamline clinical workflows.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

Here we pick three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

Are Investors Undervaluing Fresenius Medical Care AG & Co. (FMS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Fresenius Medical (FMS) Sinks on Potential Rise in Competition

Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.